Regulation Of Adverse Event Reporting For Biotech Drugs In Morocco.
1. Introduction
The regulation of adverse event reporting for biotechnology-based medicinal products in Morocco is an important component of pharmaceutical law, public health protection, patient safety and regulatory accountability.
Biotech drugs are medicinal products developed through biological processes involving living cells, microorganisms, recombinant DNA technology, monoclonal antibodies, genetic engineering or other advanced biological techniques.
Examples include:
Monoclonal antibodies used in cancer treatment.
Recombinant insulin and growth hormones.
Gene and cell therapies.
Biotechnology-derived vaccines.
Recombinant blood products.
Biosimilars and other biological medicines.
Unlike conventional chemical medicines, biotechnology-derived products may have complex molecular structures, immunogenicity risks, batch variability and potentially unpredictable biological effects.
Consequently, adverse event reporting is essential for detecting previously unknown risks, identifying manufacturing-related problems, monitoring long-term safety and ensuring that the benefits of a medicine continue to outweigh its risks.
In Morocco, this subject must be understood through pharmaceutical legislation, marketing authorisation requirements, pharmacovigilance institutions, health-professional reporting obligations and the regulatory supervision of biological medicinal products.
2. Legal framework governing adverse event reporting in Morocco
The Moroccan framework is based on several legislative and institutional instruments.
A. Law No. 17-04: Code of Medicine and Pharmacy
Law No. 17-04, promulgated by Dahir No. 1-06-151 of 22 November 2006, is a central instrument governing medicinal products in Morocco.
It establishes the legal framework for:
Pharmaceutical manufacturing and distribution.
Marketing authorisation of medicinal products.
Quality and safety requirements.
Regulatory supervision of pharmaceutical establishments.
Responsibilities of manufacturers and importers.
Control of medicinal products placed on the Moroccan market.
Article 8 is particularly relevant because it requires appropriate prior testing and manufacturing and control methods capable of ensuring the quality of medicines during industrial production.
Articles 12 and 13 also regulate changes to marketing authorisations and the obligation to inform the administration about relevant changes.
Application to biotechnology drugs: A manufacturer cannot treat regulatory approval as the end of its safety obligations. If adverse events reveal a quality defect, contamination, immunogenicity problem or manufacturing inconsistency, the information may justify regulatory reassessment or other protective measures.
Source: WIPO – Moroccan Law No. 17-04.
B. Decree No. 2-14-841 concerning marketing authorisation
Decree No. 2-14-841 regulates marketing authorisation for medicines intended for human use.
Its relevance to biotech products includes:
Assessment of pharmaceutical quality.
Evaluation of safety and efficacy.
Examination of manufacturing information.
Regulatory review before marketing.
Supervision of the authorised product.
For biological medicines, the quality and consistency of the manufacturing process are especially important because small variations in production can potentially affect the product's biological characteristics.
Adverse event reports received after authorisation may therefore reveal issues that were not apparent during clinical development.
C. Framework Law No. 34-09 on the health system
Framework Law No. 34-09 concerning the health system and the provision of healthcare establishes a broader framework for health-system organisation and management of health risks.
It is relevant to pharmacovigilance because adverse event reporting depends on cooperation between healthcare institutions, medical professionals, pharmaceutical authorities and patients.
D. Law No. 27-26: Strengthening pharmaceutical vigilance
An important recent development is Law No. 27-26, which modifies and supplements Law No. 17-04.
The Moroccan Parliament adopted the legislative project on 8 June 2026. The reform aims to strengthen the powers of the Moroccan Agency for Medicines and Health Products (AMMPS), institutionalise pharmaceutical vigilance and increase the responsibility of industrial pharmaceutical establishments for monitoring medicine safety after marketing.
In September 2026, AMMPS issued a specific notice concerning the appointment of a person exclusively responsible for pharmacovigilance, referring to Articles 7 and 120 of Law No. 27-26.
The notice requires the designated person to:
Be a pharmacist or physician.
Have relevant pharmacovigilance competencies.
Possess knowledge of epidemiology and biostatistics.
Reside in Morocco.
Work full-time on pharmacovigilance.
Be available 24 hours a day, seven days a week.
The notice established 16 October 2026 as the deadline for the relevant industrial pharmaceutical establishments to complete the designation.
This reform is particularly significant for biotechnology manufacturers because it strengthens institutional responsibility for detecting, investigating and communicating adverse events.
Sources: Moroccan Parliament – Bill No. 27-26; AMMPS – Pharmacovigilance appointment requirements; Moroccan Ministry of Health – Legislative reform.
Legal-status qualification: Parliamentary adoption, promulgation and publication in the Official Bulletin are distinct legislative stages. The AMMPS September 2026 notice confirms that it was applying the cited provisions for the appointment requirement; the final consolidated statutory text should be consulted for the complete current obligations.
3. Institutional framework for adverse event reporting
The Moroccan pharmacovigilance system operates through specialised public health institutions.
A. Moroccan Agency for Medicines and Health Products (AMMPS)
The Moroccan Agency for Medicines and Health Products (AMMPS) is responsible for pharmaceutical regulatory oversight.
Its functions include:
Monitoring medicine safety.
Supervising pharmacovigilance activities.
Receiving and evaluating safety information.
Coordinating regulatory risk-management measures.
Supporting the safe use of medicines.
Communicating relevant safety information.
B. National Centre for Health Vigilance and Risk Management
The National Centre for Health Vigilance and Risk Management is responsible for monitoring, analysing and preventing risks associated with medicines and health products after they enter the market.
Its work includes pharmacovigilance for medicines and vaccinovigilance for vaccines.
C. Regional vigilance centres
Regional centres facilitate the collection and transmission of adverse event information from healthcare institutions and professionals.
They help identify:
Unexpected reactions.
Serious adverse events.
Repeated reactions associated with particular medicines.
Possible manufacturing or quality problems.
Regional patterns of medicine-related harm.
D. Healthcare institutions
Hospitals, clinics, laboratories and pharmacies play an important role in identifying suspected adverse reactions.
They should maintain appropriate procedures for documenting suspected reactions, communicating safety concerns and cooperating with the competent authorities.
The Ministry of Health's published description of the national system also identifies the National Pharmacovigilance Centre, regional centres, a Technical Pharmacovigilance Committee and a National Pharmacovigilance Commission.
sante.gov.ma+1
4. What constitutes an adverse event involving a biotech drug?
An adverse event is an undesirable medical occurrence following the use of a medicinal product. It does not automatically establish that the medicine caused the event.
An adverse drug reaction involves a suspected harmful response associated with the medicine.
For biotechnology products, the following categories deserve particular attention.
| Category | Example |
|---|---|
| Immunogenicity | Formation of anti-drug antibodies |
| Hypersensitivity | Severe allergic or anaphylactic reaction |
| Immunological complications | Cytokine release syndrome |
| Infectious complications | Unexpected infection associated with immunosuppression |
| Haematological effects | Severe neutropenia or thrombocytopenia |
| Manufacturing defects | Contamination or product instability |
| Batch-related reactions | Unexpected reactions associated with a particular batch |
| Long-term effects | Delayed immune or other biological complications |
For example, a patient receiving a monoclonal antibody for cancer treatment may develop a severe immune-mediated reaction.
The reporting system should capture the suspected reaction even if the precise biological mechanism has not yet been established.
5. Who has responsibility for reporting?
Adverse event reporting involves several categories of participants.
A. Pharmaceutical manufacturers
Manufacturers must maintain appropriate pharmacovigilance arrangements and investigate safety information relating to their products.
Their responsibilities include:
Collecting adverse event reports.
Maintaining safety records.
Evaluating potential product-related risks.
Identifying emerging safety signals.
Communicating relevant information to the regulator.
Supporting corrective and preventive measures.
The strengthened framework under Law No. 27-26 places particular emphasis on the responsibility of industrial pharmaceutical establishments.
B. Importers and distributors
Importers and distributors may receive complaints or safety information concerning imported biotechnology medicines.
They should have mechanisms for transmitting relevant information to the responsible pharmaceutical establishment and competent authorities.
C. Doctors and other healthcare professionals
Healthcare professionals are important sources of adverse event information because they can identify clinical changes, assess treatment histories and provide medical documentation.
D. Patients and users
Morocco's official notification system allows patients and users to report suspected adverse events directly.
This is important because a patient may experience a reaction outside a hospital or discover a delayed complication after completing treatment.
The AMMPS reporting portal expressly identifies patients, healthcare professionals and companies manufacturing, importing or distributing health products as potential reporters.
AMMPS+1
6. Procedure for reporting adverse events in Morocco
The reporting process should be organised to ensure that suspected adverse reactions are recorded, investigated and communicated without unnecessary delay.
Identification of the adverse event
A patient, doctor, pharmacist or manufacturer identifies an unexpected or suspected harmful event following administration of a biotechnology medicine.
Collection of clinical information
The reporter records the patient's relevant medical history, suspected medicine, dosage, batch number, administration date, symptoms and clinical outcome.
Initial reporting
The suspected event is submitted through the appropriate AMMPS reporting channel. Reporting should not be unnecessarily delayed while waiting for proof of causation.
Regulatory assessment
The competent pharmacovigilance authorities evaluate the report, assess its seriousness and investigate whether other similar cases have been recorded.
Signal detection
Multiple reports may reveal an emerging safety signal involving a particular medicine, manufacturing process or batch.
Regulatory intervention
Depending on the evidence, authorities may consider further investigation, safety communications, changes to product information, restrictions, suspension or withdrawal of marketing authorisation.
Information required in an adverse event report
A useful report should contain:
Patient identification or an appropriate confidential patient identifier.
Patient age and relevant medical history.
Name and presentation of the suspected biological medicine.
International Nonproprietary Name (INN).
Manufacturer and product batch or lot number, where available.
Dosage, route and dates of administration.
Description of the suspected adverse reaction.
Date of onset and duration.
Laboratory and diagnostic findings.
Treatment provided for the reaction.
Clinical outcome.
Details of the reporting healthcare professional or other reporter.
For biological medicines, batch identification is especially important. Two products with the same active substance may have different manufacturing histories, and a cluster of reactions associated with one batch may indicate a quality problem.
Current reporting channels
Official reporting available
AMMPS provides electronic and paper-based reporting channels for medicines and vaccines.
AMMPS – Report an adverse event.
VigiMobile is the mobile application for reporting adverse events involving medicines and vaccines.
VIGIUP is a complementary platform for other categories of health products.
Paper notification forms can also be submitted using the instructions provided by AMMPS.
AMMPS announced the launch of VigiMobile and VIGIUP in November 2026 as part of the modernisation of the national vigilance system.
ammps.gov.ma+1
7. Special regulatory requirements for biotechnology medicines
Biotechnology-derived medicinal products require particular attention because their safety characteristics may differ from those of conventional medicines.
A. Immunogenicity monitoring
Biological medicines may stimulate immune responses, including the production of anti-drug antibodies.
These antibodies may:
Reduce therapeutic effectiveness.
Alter the medicine's biological activity.
Produce hypersensitivity reactions.
Cause unexpected clinical complications.
Regulators should therefore consider immunogenicity information when evaluating adverse event reports.
B. Biosimilar safety monitoring
Biosimilars are biological medicines developed to be highly similar to an already authorised reference biological medicine.
Their pharmacovigilance systems should identify the actual product administered, including the brand name and batch number.
This helps distinguish adverse reactions associated with a particular product from those associated with the active biological substance more generally.
C. Batch traceability
Batch traceability is essential for investigating possible manufacturing defects.
For example, if several patients develop unexpected reactions after receiving the same batch of a recombinant biological medicine, the regulator may investigate:
Manufacturing conditions.
Sterility.
Storage and transportation.
Product stability.
Packaging integrity.
Distribution records.
D. Risk management plans
A risk management plan should identify important known and potential risks and explain how they will be monitored and minimised.
For high-risk biotechnology medicines, the plan may include additional safety monitoring, specialised patient follow-up and targeted educational measures.
E. Post-authorisation safety surveillance
Approval does not eliminate the need for continued monitoring.
Some biological complications become apparent only after prolonged treatment or exposure in a larger and more diverse population.
This makes post-marketing surveillance a fundamental part of biotech medicine regulation.
8. Important case laws and judicial decisions
An important distinction must be made: Moroccan pharmaceutical legislation and administrative decisions provide the primary domestic framework, but published Moroccan judgments specifically concerning failure to report adverse events involving biotechnology medicines are limited.
The following cases are relevant to manufacturer liability, vaccine safety, defective biological products and the legal consequences of inadequate safety information.
Case 1. Casablanca Court of Appeal – Engerix-B vaccine decision
Moroccan judicial decision
Court: Casablanca Court of Appeal.
Decision No.: 1437.
Date: 3 March 2009.
Case No.: 2007/1/7448.
Product: Engerix-B hepatitis B vaccine.
Manufacturer: SmithKline Beecham.
Facts
The litigation concerned a child who allegedly suffered severe paralysis following administration of the Engerix-B hepatitis B vaccine.
The child's family pursued civil and criminal claims against the manufacturer.
The reported decision concerned the manufacturer's responsibility for the serious injury and an award of compensation reported as 500 million centimes.
Legal issues
The case raises important questions concerning:
Manufacturer responsibility for harm allegedly caused by a vaccine.
The safety obligations associated with biological medicinal products.
The relationship between product defects and personal injury.
Compensation for serious injury resulting from pharmaceutical products.
Relevance to adverse event reporting
Although the reported dispute concerned product-related injury rather than a specific failure to report an adverse event to the pharmacovigilance authority, it demonstrates why vaccine safety information must be collected and evaluated.
If a manufacturer receives reports of similar serious reactions, failure to investigate or appropriately communicate relevant safety information may become significant evidence in subsequent regulatory or civil proceedings.
Legal significance: This is a particularly relevant Moroccan example because vaccines are biological medicinal products and their safety depends on continuing surveillance after marketing.
Source: Morocco Law – Report of the Casablanca Court of Appeal decision.
Research qualification: The accessible report is a secondary legal publication, not the complete official judgment. The precise reasoning, evidentiary findings and scope of the award should be checked against the original court record before relying on it in litigation.
Case 2. Declan O'Byrne v Sanofi Pasteur MSD Ltd and Sanofi Pasteur SA
European Court of Justice
Court: Court of Justice of the European Union.
Case: C-127/04.
Judgment: 9 February 2006.
Facts
The case involved a child who suffered serious injury following administration of an anti-Haemophilus vaccine.
The litigation concerned the identity of the producer and the responsibility of entities involved in the distribution chain.
Legal issue
The Court considered the meaning of a producer under the European product-liability framework and the relationship between manufacturers and closely connected distribution subsidiaries.
Decision and principle
The Court explained that determining the producer may require examination of the actual relationship between the entities and their participation in the manufacturing and distribution process.
Relevance to Morocco
This judgment is useful when considering the responsibilities of:
Biological medicine manufacturers.
Local pharmaceutical subsidiaries.
Importers.
Distribution companies.
Marketing authorisation holders.
Where a Moroccan patient experiences a serious adverse reaction, identifying the legally responsible manufacturer and the relevant pharmaceutical operator is important for regulatory investigations and compensation claims.
The case also illustrates why pharmacovigilance records must identify the product and the entities responsible for its supply.
Source: CJEU – Declan O'Byrne v Sanofi Pasteur.
Case 3. LF v Sanofi Pasteur SA
Recent CJEU judgment – 2026
Court: Court of Justice of the European Union.
Case: C-338/24.
Judgment: 26 March 2026.
Facts and legal questions
The case concerned product liability relating to a vaccine and addressed the relationship between defective-product liability and fault-based liability.
The Court also considered limitation periods in cases involving progressive illness and the interpretation of when an injured person becomes aware of the damage.
Legal significance
The judgment is relevant to pharmaceutical injury litigation because it addresses:
The legal consequences of defective medicinal products.
The relationship between different liability regimes.
The commencement of limitation periods.
Access to judicial remedies for injured persons.
Relevance to Moroccan law
Although the decision is not binding on Moroccan courts, it provides useful comparative guidance when considering claims involving biological medicines.
It also highlights the importance of preserving pharmacovigilance records, medical documentation and evidence concerning when the adverse effects first became apparent.
Source: CJEU – LF v Sanofi Pasteur SA, C-338/24.
9. Legal liability for failure to report adverse events
Failure to report or properly investigate adverse events may create different forms of legal exposure.
A. Civil liability
A pharmaceutical manufacturer may face civil liability where a defective biological medicine causes injury and the necessary legal elements are established.
Potential grounds include:
Negligence in manufacturing.
Failure to investigate known safety concerns.
Failure to provide adequate warnings.
Inadequate quality-control procedures.
Failure to take appropriate corrective action.
Articles 77 and 78 of the Moroccan Dahir of Obligations and Contracts provide important general principles concerning liability for wrongful acts and negligence.
B. Administrative liability
Regulatory authorities may take action where pharmaceutical establishments fail to comply with applicable pharmaceutical requirements.
Possible measures, depending on the legal basis and seriousness of the breach, include:
Regulatory inspections.
Requests for corrective action.
Restrictions on distribution.
Product recalls.
Suspension or withdrawal of authorisation.
Other applicable administrative sanctions.
C. Criminal liability
Where conduct involving pharmaceutical products constitutes an offence under applicable Moroccan legislation, criminal proceedings may arise.
For example, deliberate concealment of serious product defects, falsification of safety documentation or unlawful distribution of unsafe medicines may raise criminal-law issues.
However, the precise offence and penalties must be established under the applicable statutory provisions. A delayed or incomplete adverse event report does not automatically constitute a criminal offence.
D. Patient rights and compensation
Patients who suffer injury from biotechnology medicines may seek appropriate legal remedies where the conditions for liability are satisfied.
Important considerations include:
Medical evidence.
Product identification.
Causation.
Manufacturing records.
Adverse event reports.
Expert medical opinions.
Evidence of regulatory non-compliance.
10. Major regulatory challenges in Morocco
Despite institutional improvements, several challenges deserve attention.
| Regulatory challenge | Legal and practical concern |
|---|---|
| Underreporting | Serious reactions may remain unidentified |
| Limited specialist training | Healthcare professionals may overlook biological complications |
| Batch traceability | Difficulties identifying defective production batches |
| Biosimilar identification | Confusion between different biological products |
| Delayed reporting | Slower regulatory intervention |
| Data protection | Protection of confidential patient information |
| International coordination | Difficulty exchanging safety information across jurisdictions |
| Manufacturer accountability | Insufficient investigation of emerging safety signals |
Another important challenge is the availability of specialised expertise for assessing complex biological reactions. Evaluating immunogenicity, gene therapy complications and delayed immune responses requires appropriate scientific and clinical capabilities.
11. International regulatory standards relevant to Morocco
Morocco can strengthen its national system by drawing on established international pharmacovigilance standards.
A. World Health Organization
The World Health Organization promotes international pharmacovigilance cooperation through its Programme for International Drug Monitoring.
The programme supports the collection and analysis of suspected adverse drug reactions and international safety-signal detection.
B. European Union pharmacovigilance framework
The European Union's pharmacovigilance legislation provides useful comparative principles concerning:
Individual case safety reports.
Periodic safety update reports.
Risk management plans.
Pharmacovigilance system master files.
Safety signal detection.
Post-authorisation safety studies.
C. International Council for Harmonisation
ICH guidelines provide internationally recognised approaches to pharmacovigilance and pharmaceutical safety.
Particularly relevant guidelines include:
ICH E2A: Clinical Safety Data Management.
ICH E2B: Electronic Transmission of Individual Case Safety Reports.
ICH E2C: Periodic Benefit-Risk Evaluation Reports.
ICH E2D: Post-Approval Safety Data Management.
ICH E2E: Pharmacovigilance Planning.
These standards can assist Morocco in developing consistent reporting, documentation and risk-assessment procedures.
12. Recommendations for strengthening Moroccan biotech pharmacovigilance
Several improvements could strengthen the regulatory system.
1. Mandatory electronic reporting: Expand digital reporting and integrate healthcare institutions with the national pharmacovigilance system.
2. Biological batch traceability: Require systematic recording of product names, manufacturers and batch numbers.
3. Specialised reporting procedures: Develop reporting guidance for gene therapies, monoclonal antibodies, biosimilars and cell-based medicines.
4. Manufacturer accountability: Ensure that pharmaceutical establishments maintain properly resourced pharmacovigilance systems.
5. Professional training: Provide regular training for doctors, pharmacists, nurses and laboratory specialists.
6. Patient participation: Improve public awareness of adverse event reporting channels.
7. International information exchange: Strengthen cooperation with WHO and international pharmacovigilance networks.
8. Judicial accountability: Improve access to safety documentation and expert evidence in pharmaceutical injury litigation.
9. Data protection: Ensure that adverse event reporting respects confidentiality and applicable personal-data protection requirements.
10. Independent safety assessment: Strengthen scientific review of serious and unexpected adverse events involving biological medicines.
13. Illustrative legal hypothetical
Consider a Moroccan patient receiving a recombinant biological medicine for cancer treatment.
After several administrations, the patient develops a severe immune-mediated reaction. The hospital discovers that two other patients receiving the same batch experienced similar complications.
The following legal questions arise:
Did the hospital appropriately document and report the suspected reactions?
Did the manufacturer investigate the batch?
Was the relevant safety information communicated to AMMPS?
Was there a manufacturing or storage defect?
Did the manufacturer take appropriate corrective action?
Did the regulatory authority have sufficient information to consider a recall or other intervention?
If the manufacturer knew of a serious emerging safety signal but failed to investigate or communicate it as required by applicable law, that failure could become relevant to regulatory enforcement and civil liability.
However, the existence of several reports does not automatically prove that the product was defective. Scientific investigation and evidence of causation remain essential.
14. Conclusion
The regulation of adverse event reporting for biotechnology medicines in Morocco is an essential component of pharmaceutical safety and public health governance.
Law No. 17-04 provides the foundational pharmaceutical framework, while Decree No. 2-14-841 addresses marketing authorisation. The institutional pharmacovigilance system, operated through AMMPS and its vigilance structures, provides mechanisms for identifying and evaluating suspected adverse reactions.
The 2026 pharmaceutical reform under Law No. 27-26 represents an important development by strengthening the institutional responsibilities of pharmaceutical establishments and the organisation of pharmacovigilance.
The Casablanca Court of Appeal's Engerix-B vaccine decision also demonstrates the importance of manufacturer accountability where serious injury is alleged to result from a biological medicinal product.
Ultimately, effective regulation requires more than granting marketing authorisation. It requires continuous safety monitoring, timely reporting, scientific investigation, transparent communication, product traceability and effective legal remedies for injured patients.
The central legal principle is that pharmaceutical safety is a continuing responsibility extending throughout the entire lifecycle of a biotechnology medicine, from development and authorisation to manufacturing, distribution and post-marketing surveillance.
15. Important legal and regulatory references
| Instrument / decision | Relevance |
|---|---|
| Moroccan Law No. 17-04 | Code of Medicine and Pharmacy |
| Decree No. 2-14-841 | Marketing authorisation for human medicines |
| Framework Law No. 34-09 | Health-system organisation and risk management |
| Law No. 27-26 | Pharmaceutical regulatory reform |
| Dahir of Obligations and Contracts, Arts. 77–78 | Civil liability |
| Casablanca Court of Appeal, Decision 1437 (2009) | Engerix-B vaccine injury |
| CJEU, C-127/04 (2006) | Vaccine manufacturer and producer identification |
| CJEU, C-338/24 (2026) | Vaccine product liability and limitation periods |
Official resources for further research
Moroccan Ministry of Health – Pharmaceutical legislation.
AMMPS – Adverse event reporting.
AMMPS – Pharmacovigilance responsibilities.
Moroccan Parliament – Law No. 27-26 legislative record.
Academic note: The Moroccan Engerix-B decision is a directly relevant domestic vaccine-liability example, but it should not be misrepresented as a judgment specifically imposing liability for pharmacovigilance reporting failures. The comparative European judgments likewise provide persuasive academic context, not binding Moroccan precedent.

comments